THERAPY DOSSIER · th-dee3caad748b

PHA 568487 (alpha-7 nicotinic acetylcholine receptor agonist) and methyllycaconitine (antagonist)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Fracture
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27914011 ↗2016Mixed findings

Activation of Alpha-7 Nicotinic Acetylcholine Receptor Reduces Brain Edema in Mice with Ischemic Stroke and Bone Fracture.

MouseFractureTibiaC57BL/6JMalen = 6 mice per group across 10 groupsInjection; route not specified in the textPHA 568487 0.8 mg/kg and methyllycaconitine 6 mg/kg, dilute…On days 1 and 2 after occlusion, with tibia fracture on day 1

Model: Permanent distal middle cerebral artery occlusion by electrocoagulation through a 2.0 mm burr hole, followed 24 hours later by an open right hind limb tibia fracture with intramedullary fixation

PHA 568487 reduced ipsilateral brain water content in stroke (83.0 to 81.5%, p = 0.023) and stroke with fracture (84.4 to 82.2%, p < 0.001) and reduced monoamine oxidase B positive astrocytes, whereas methyllycaconitine had the opposite effect.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…